News | September 07, 2008

Inverness Medical Launches Portable Blood Testing to Warn Patients of Potential Blood Clots

September 8. 2008 - Inverness Medical Physician Diagnostics Group, a division of Inverness Medical Innovations, today launched the INRatio2 PT/INR Monitoring System, a portable device that measures blood-clotting time, also known as prothrombin time, using one drop of blood from a patient’s finger.

The INRatio2 is used by healthcare professionals and their patients in the management of warfarin, a blood-thinning drug, to monitor the effectiveness of the drug and warn of potential blood clots and other bleeding risks. Warfarin, also sold under the brand name Coumadin, is prescribed to patients to prevent blood clots, heart attacks, deep vein thrombosis, and stroke. Warfarin is the second most common cause of emergency room visits related to adverse drug events, trailing only insulin. The FDA estimates 2 million Americans start taking warfarin every year, and many will take the drug for the rest of their lives. Due to the serious bleeding risks associated with warfarin, the FDA has labeled it with a “black box” warning, informing consumers of the major and potentially fatal risks, and indicating that patients should have their PT/INR monitored regularly.

The INRatio2 PT/INR Monitoring System has been cleared by the FDA for warfarin patients to test themselves at home, offering patients quick access to their PT/INR results. The test results are then transmitted to their treating physician by telephone or the Internet. The results provide important data that helps physicians make informed warfarin dosing adjustments to ensure that patients stay within their recommended therapeutic range. Warfarin can be difficult to manage due to the wide variance in each patient’s response to the drug, in addition to factors such as diet, age, illness, and interaction with other drugs, the company said.

The INRatio2 offers many patient-friendly features, including a one-minute test time, easy single button interface, and 200-test battery life. Its simple fingerstick test procedure, light weight (9.3 oz), and individually-sealed test strip packaging enables patients to easily test themselves at home or when traveling.

For more information: www.hemosense.com

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init